Literature DB >> 19301087

Type 1 autoimmune hepatitis and adipokines: new markers for activity and disease progression?

Marilena Durazzo1, Grazia Niro, Alberto Premoli, Enrico Morello, Erik Rosa Rizzotto, Roberto Gambino, Simona Bo, Giovanni Musso, Maurizio Cassader, Gianfranco Pagano, Annarosa Floreani.   

Abstract

PURPOSE: Cytokines may play an important role as inflammatory factors in liver diseases. There is some evidence suggesting a link between adiponectin-biliary function and liver disease. The aim of this study was to clarify the behavior of adipokines in autoimmune hepatitis type 1.
METHODS: We assessed the circulating levels of adiponectin, tumor necrosis factor-alpha, resistin and leptin in 42 patients with autoimmune hepatitis, comparing them with 42 healthy subjects who were matched for age and sex and with 31 patients with nonalcoholic steatohepatitis (NASH), evaluating the associations with markers of cytolysis, cholestasis, and histological severity.
RESULTS: Adiponectin and TNF-alpha values were higher in patients compared to controls. The patients showed significantly higher Homeostasis Model Assessment values, suggesting an increased insulin resistance and serum levels of adiponectin positively correlated with gamma-glutamyltranspeptidase and alkaline phosphatase values after a simple regression analysis. Serum levels of resistin positively correlated with elevated aminotransferases and bilirubin values, and serum levels of TNF-alpha positively correlated with elevated alanine-aminotransferase and resistin values. The concentration of adiponectin increased significantly with staging of the disease. Patients with NASH showed lower levels of adiponectin and higher levels of resistin than AIH patients and controls.
CONCLUSIONS: Patients with AIH showed significantly higher adiponectin concentrations than controls despite their higher HOMA-IR values. The significant correlation between adiponectin levels and serological features of cholestasis suggested an association with biliary function. Our results indicate that adiponectin may be a possible marker for disease progression in AIH.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19301087     DOI: 10.1007/s00535-009-0023-0

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  35 in total

Review 1.  Autoimmune hepatitis.

Authors:  Diego Vergani; Giorgina Mieli-Vergani
Journal:  Autoimmun Rev       Date:  2003-09       Impact factor: 9.754

2.  White adipose tissue, inert no more!

Authors:  Joseph P McGillis
Journal:  Endocrinology       Date:  2005-05       Impact factor: 4.736

3.  International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis.

Authors:  F Alvarez; P A Berg; F B Bianchi; L Bianchi; A K Burroughs; E L Cancado; R W Chapman; W G Cooksley; A J Czaja; V J Desmet; P T Donaldson; A L Eddleston; L Fainboim; J Heathcote; J C Homberg; J H Hoofnagle; S Kakumu; E L Krawitt; I R Mackay; R N MacSween; W C Maddrey; M P Manns; I G McFarlane; K H Meyer zum Büschenfelde; M Zeniya
Journal:  J Hepatol       Date:  1999-11       Impact factor: 25.083

Review 4.  The evolving role of leptin and adiponectin in chronic liver diseases.

Authors:  Emmanuel Tsochatzis; George V Papatheodoridis; Athanasios J Archimandritis
Journal:  Am J Gastroenterol       Date:  2006-09-04       Impact factor: 10.864

5.  Associations between plasma adiponectin concentrations and liver histology in patients with nonalcoholic fatty liver disease.

Authors:  Giovanni Targher; Lorenzo Bertolini; Stefano Rodella; Giacomo Zoppini; Luca Scala; Luciano Zenari; Giancarlo Falezza
Journal:  Clin Endocrinol (Oxf)       Date:  2006-06       Impact factor: 3.478

6.  Soluble tumor necrosis factor receptors in chronic hepatitis C: a correlation with histological fibrosis and activity.

Authors:  H Zylberberg; A C Rimaniol; S Pol; A Masson; D De Groote; P Berthelot; J F Bach; C Bréchot; F Zavala
Journal:  J Hepatol       Date:  1999-02       Impact factor: 25.083

7.  Adiponectin is markedly increased in patients with nephrotic syndrome and is related to metabolic risk factors.

Authors:  Carmine Zoccali; Francesca Mallamaci; Vincenzo Panuccio; Giovanni Tripepi; Sebastiano Cutrupi; Saverio Parlongo; Francesco Catalano; Sachiyo Tanaka; Noriyuki Ouchi; Shinji Kihara; Tohru Funahashi; Yuji Matsuzawa
Journal:  Kidney Int Suppl       Date:  2003-05       Impact factor: 10.545

8.  Elevated plasma resistin concentrations in patients with liver cirrhosis.

Authors:  Satoru Kakizaki; Naondo Sohara; Yuichi Yamazaki; Norio Horiguchi; Daisuke Kanda; Kenji Kabeya; Kenji Katakai; Ken Sato; Hitoshi Takagi; Masatomo Mori
Journal:  J Gastroenterol Hepatol       Date:  2008-01       Impact factor: 4.029

9.  Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes.

Authors:  Anna M Wolf; Dominik Wolf; Holger Rumpold; Barbara Enrich; Herbert Tilg
Journal:  Biochem Biophys Res Commun       Date:  2004-10-15       Impact factor: 3.575

10.  Associations of adiponectin with body fat distribution and insulin sensitivity in nondiabetic Hispanics and African-Americans.

Authors:  Anthony J G Hanley; Donald Bowden; Lynne E Wagenknecht; Aarthi Balasubramanyam; Carl Langfeld; Mohammed F Saad; Jerome I Rotter; Xiuqing Guo; Yii-Der I Chen; Michael Bryer-Ash; Jill M Norris; Steven M Haffner
Journal:  J Clin Endocrinol Metab       Date:  2007-04-10       Impact factor: 5.958

View more
  8 in total

1.  Evaluation of risk factors for the development of cirrhosis in autoimmune hepatitis: Japanese NHO-AIH prospective study.

Authors:  Kiyoshi Migita; Yukio Watanabe; Yuka Jiuchi; Yoko Nakamura; Akira Saito; Michiyasu Yagura; Hideo Morimoto; Masaaki Shimada; Eiji Mita; Taizo Hijioka; Haruhiro Yamashita; Eiichi Takezaki; Toyokichi Muro; Hironori Sakai; Makoto Nakamuta; Seigo Abiru; Koji Yano; Atsumasa Komori; Hiroshi Yatsuhashi; Minoru Nakamura; Hiromi Ishibashi
Journal:  J Gastroenterol       Date:  2010-11-02       Impact factor: 7.527

2.  Efficacy of ursodeoxycholic acid for Japanese patients with autoimmune hepatitis.

Authors:  Yasuhiro Miyake; Yoshiaki Iwasaki; Haruhiko Kobashi; Tetsuya Yasunaka; Fusao Ikeda; Akinobu Takaki; Ryoichi Okamoto; Kouichi Takaguchi; Hiroshi Ikeda; Yasuhiro Makino; Masaharu Ando; Kohsaku Sakaguchi; Kazuhide Yamamoto
Journal:  Hepatol Int       Date:  2009-10-22       Impact factor: 6.047

3.  Serum Biomarkers for Autoimmune Hepatitis Type 1: the Case for CD48 and a Review of the Literature.

Authors:  Mingli Hu; Zhengrui You; You Li; Bingyuan Huang; Nana Cui; Rui Wang; Yiran Wei; Bo Li; Jubo Liang; Qiaoyan Liu; Yikang Li; Hanxiao Wang; Qiwei Qian; Jun Zhang; Ruiling Chen; Zhuwan Lyu; Yong Chen; Xiao Xiao; Min Lian; Ruqi Tang; Qi Miao; Qixia Wang; Xiong Ma
Journal:  Clin Rev Allergy Immunol       Date:  2022-06-03       Impact factor: 8.667

4.  Bile acid-induced inflammatory signaling in mice lacking Foxa2 in the liver leads to activation of mTOR and age-onset obesity.

Authors:  Irina Mikhailovna Bochkis; Soona Shin; Klaus Hermann Kaestner
Journal:  Mol Metab       Date:  2013-08-24       Impact factor: 7.422

5.  Variations of serum levels of adiponectin and resistin in chronic viral hepatitis.

Authors:  M Durazzo; P Belci; G Niro; A Collo; E Grisoglio; V Ambrogio; M Spandre; R Fontana; R Gambino; M Cassader; S Bo
Journal:  J Endocrinol Invest       Date:  2013-02-27       Impact factor: 4.256

6.  Serum Leptin Serves as an Inflammatory Activity Marker and Predicts Steroid Response in Autoimmune Hepatitis.

Authors:  Deepika Lal; Monika Thakur; Chhagan Bihari
Journal:  J Clin Exp Hepatol       Date:  2020-04-27

7.  Association of serum adiponectin, leptin, and resistin concentrations with the severity of liver dysfunction and the disease complications in alcoholic liver disease.

Authors:  Beata Kasztelan-Szczerbinska; Agata Surdacka; Maria Slomka; Jacek Rolinski; Krzysztof Celinski; Agata Smolen; Mariusz Szczerbinski
Journal:  Mediators Inflamm       Date:  2013-10-23       Impact factor: 4.711

Review 8.  Roles of Adipokines in Digestive Diseases: Markers of Inflammation, Metabolic Alteration and Disease Progression.

Authors:  Ming-Ling Chang; Zinger Yang; Sien-Sing Yang
Journal:  Int J Mol Sci       Date:  2020-11-05       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.